GlassScriptPhysician profile
Aminu Mohammed
NPI 1477517399
$801.97
in general payments reported to CMS, 2019-2025
12 companies · $86.75 in 2025
The $86.75 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2022: $13.01 · 2023: $80.86 · 2024: $380 · 2025: $86.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $130.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $123.56 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $122.49 | 2024-2025 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $111.68 | 2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $110.22 | 2019 | |
| Genzyme Corporation | $63.97 | 2022-2025 | |
| Qol Medical, LLC | $48.53 | 2023 | Sucraid |
| Medtronic, INC. | $36.29 | 2024 | Interstim |
| Abbvie INC. | $21.96 | 2025 | |
| Fresenius Kabi USA, LLC | $18.85 | 2023 | Idacio |
| Janssen Biotech, INC. | $13.48 | 2023 | Stelara |
| Travere Therapeutics, INC. | $0.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aminu Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.